RANK Ligand - Metabolism
Research News and Information

Sunday, November 22, 2009

Colony-stimulating factor-1 (CSF-1) directly inhibits receptor activator of nuclear factor-{kappa}B ligand (RANKL) expression by osteoblasts.

7 Oct 2009 Colony-stimulating factor-1 (CSF-1), released by osteoblasts, stimulates the proliferation of osteoclast progenitors via the c-fms receptor (CSF-1R) and, in combination with receptor activator of nuclear factor-kappaB ligand (RANKL), leads to the ... Read more...

Accelerated cartilage resorption by chondroclasts during bone fracture healing in osteoprotegerin-deficient mice.

7 Oct 2009 Receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin (OPG), a decoy receptor of RANKL, maintain bone mass by regulating the differentiation of osteoclasts, which are bone-resorbing cells. Endochondral bone ossification and ... Read more...

Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin.

6 Oct 2009 Autoantibodies against osteoprotegerin, which block the inhibitory effect of osteoprotegerin on signaling by the receptor activator of nuclear factor (NF)-kappaB (RANK), were identified in a man with celiac disease who presented with severe ... Read more...

Latest indexed articles for 'RANK Ligand - Metabolism'

These are the very latest articles for this heading:

• Colony-stimulating factor-1 (CSF-1) directly inhibits receptor activator of nuclear factor-{kappa}B ligand (RANKL) expression by osteoblasts. 7 Oct 2009
• Accelerated cartilage resorption by chondroclasts during bone fracture healing in osteoprotegerin-deficient mice. 7 Oct 2009
• Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. 6 Oct 2009
• Cocultures of osteoblasts and osteoclasts are influenced by local application of zoledronic acid incorporated in a poly(D,L-lactide) implant coating. 29 Sep 2009
• Sustained and localized in vitro release of BMP-2/7, RANKL, and tetracycline from FlexBone, an elastomeric osteoconductive bone substitute. 29 Sep 2009
• Direct effects of osteoprotegerin on human bone cell metabolism. 9 Sep 2009
• Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. 6 Sep 2009
• Intravenous pamidronate therapy in osteogenesis imperfecta: response to treatment and factors influencing outcome: a novel molecular mechanism. 30 Aug 2009
• Ca2+-NFATc1 signaling is an essential axis of osteoclast differentiation. 30 Aug 2009
• Osteoblast and osteoclast differentiation in an in vitro three-dimensional model of bone. 30 Aug 2009
• Tumor necrosis factor alpha and RANKL blockade cannot halt bony spur formation in experimental inflammatory arthritis. 30 Aug 2009
• Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. 30 Aug 2009
• Regulation of vacuolar H(+)-ATPase in microglia by RANKL. 24 Aug 2009
• Enhanced inhibitory effects of a novel CpG motif on osteoclast differentiation via TREM-2 down-regulation. 17 Aug 2009
• Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis. 13 Aug 2009
• Potential enhancement of osteoclastogenesis by severe acute respiratory syndrome coronavirus 3a/X1 protein. 12 Aug 2009
• VEGF and RANKL regulation of NFATc1 in heart valve development. 4 Aug 2009
• Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. 30 Jul 2009
• Expression of eight genes of nuclear factor-kappa B pathway in multiple myeloma using bone marrow aspirates obtained at diagnosis. 30 Jul 2009
• Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. 30 Jul 2009

See a longer list of these articles.

Technical information about 'RANK Ligand'

Definition: A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an important role in regulating OSTEOCLAST differentiation and activation.

Registry Number: 0

Descriptor UI: D053245

Alternative terms: RANK Ligand; Osteoclast Differentiation Factor; Differentiation Factor, Osteoclast; Osteoprotegerin Ligand; RANKL Protein; Receptor Activator of Nuclear Factor-kappa B Ligand; Receptor Activator of Nuclear Factor kappa B Ligand; TNF Superfamily, Member 11; TRANCE Protein; Tumor Necrosis Factor Ligand Superfamily Member 11; Tumor Necrosis Factor-Related Activation-Induced Cytokine; Tumor Necrosis Factor Related Activation Induced Cytokine; OPGL Protein; Receptor Activator of Nuclear Factor-kappaB Ligand; Receptor Activator of Nuclear Factor kappaB Ligand;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; drug effects; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; ultrastructure; urine; chemistry; contraindications; agonists;

Tree Number: D12.644.276.374.750.562; D12.644.276.972.562; D12.776.467.374.750.562; D12.776.467.972.562; D23.529.374.750.562; D23.529.972.562;

History Note: 2007(1997)